Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. cut its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 59.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,270 shares of the company's stock after selling 15,165 shares during the period. Landscape Capital Management L.L.C.'s holdings in Ionis Pharmaceuticals were worth $359,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in IONS. Vanguard Group Inc. lifted its holdings in shares of Ionis Pharmaceuticals by 9.4% in the 4th quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company's stock worth $575,880,000 after acquiring an additional 1,416,781 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Ionis Pharmaceuticals by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 2,687,248 shares of the company's stock worth $93,976,000 after purchasing an additional 18,890 shares during the period. Norges Bank purchased a new position in Ionis Pharmaceuticals during the 4th quarter valued at about $59,948,000. Charles Schwab Investment Management Inc. lifted its holdings in Ionis Pharmaceuticals by 2.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,481,440 shares of the company's stock worth $51,791,000 after buying an additional 38,420 shares during the period. Finally, Groupama Asset Managment grew its position in shares of Ionis Pharmaceuticals by 11.0% in the 4th quarter. Groupama Asset Managment now owns 1,017,191 shares of the company's stock worth $35,561,000 after buying an additional 101,131 shares during the last quarter. Institutional investors own 93.86% of the company's stock.

Remove Ads

Ionis Pharmaceuticals Trading Up 4.5 %

Shares of Ionis Pharmaceuticals stock traded up $1.19 on Friday, reaching $27.90. The company had a trading volume of 2,010,951 shares, compared to its average volume of 1,508,727. The firm's 50-day moving average price is $31.22 and its two-hundred day moving average price is $34.56. Ionis Pharmaceuticals, Inc. has a 1 year low of $23.95 and a 1 year high of $52.34. The firm has a market cap of $4.44 billion, a price-to-earnings ratio of -9.18 and a beta of 0.29. The company has a debt-to-equity ratio of 2.12, a current ratio of 8.47 and a quick ratio of 8.82.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.46. The firm had revenue of $227.00 million for the quarter, compared to the consensus estimate of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company's revenue for the quarter was down 30.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.12 earnings per share. As a group, research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Eric Swayze sold 7,154 shares of the company's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $32.84, for a total transaction of $234,937.36. Following the transaction, the executive vice president now directly owns 45,670 shares of the company's stock, valued at $1,499,802.80. This represents a 13.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Patrick R. O'neil sold 6,165 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total transaction of $194,937.30. Following the sale, the executive vice president now owns 57,452 shares of the company's stock, valued at $1,816,632.24. The trade was a 9.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 111,956 shares of company stock worth $3,608,439 in the last ninety days. 2.71% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

IONS has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 8th. Royal Bank of Canada restated an "outperform" rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, February 20th. BMO Capital Markets decreased their price target on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a research note on Thursday, February 20th. HC Wainwright started coverage on shares of Ionis Pharmaceuticals in a research report on Monday, April 7th. They set a "buy" rating and a $45.00 price target for the company. Finally, Redburn Atlantic assumed coverage on shares of Ionis Pharmaceuticals in a research note on Monday, March 31st. They set a "neutral" rating and a $39.00 target price for the company. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.72.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.